In the preceding three months, 13 analysts have released ratings for Boston Scientific BSX, presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 6 | 1 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 4 | 4 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $73.08, along with a high estimate of $80.00 and a low estimate of $67.00. This upward trend is evident, with the current average reflecting a 12.09% increase from the previous average price target of $65.20.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Boston Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| John Eade | Argus Research | Raises | Buy | $80.00 | $69.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $79.00 | $71.00 |
| Joshua Jennings | TD Cowen | Raises | Outperform | $77.00 | $65.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $70.00 | - |
| Joanne Wuensch | Citigroup | Raises | Buy | $71.00 | $65.00 |
| Mike Matson | Needham | Raises | Buy | $71.00 | $60.00 |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $73.00 | $67.00 |
| Steven Lichtman | Oppenheimer | Raises | Perform | $68.00 | $58.00 |
| Anthony Petrone | Mizuho | Announces | Buy | $80.00 | - |
| Shagun Singh | RBC Capital | Raises | Outperform | $70.00 | $67.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $72.00 | $60.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $72.00 | $70.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $67.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Boston Scientific. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Boston Scientific's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of Boston Scientific's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
Delving into Boston Scientific's Background
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Financial Insights: Boston Scientific
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Boston Scientific's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 14.9%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Boston Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Boston Scientific's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.65%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.46%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
